For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1144/Multiple-Myeloma-Treatments-World-Drug-Industry-and-Market-2013-2023

1. Multiple Myeloma Treatments:
World Drug Industry and Market
2013-2023
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

2. Contents
1.
Executive Summary
1.1
What This Report Covers
1.2
Multiple Myeloma: World Drug Market Overview 2013-2023
1.3
Chapter Outlines
1.4
Research and Analysis Methods
2. Introduction to Multiple Myeloma and its Treatment
2.1
What is Multiple Myeloma?
2.2
What Are Plasma Cells?
2.3
What Causes Multiple Myeloma?
2.4
Signs and Symptoms of the Disease
2.5
Demographic Risk Variation in Multiple Myeloma
2.6
Stages of the Disease
2.6.1 The Durie-Salmon Staging System and the International Staging System
2.7
Treatment of Multiple Myeloma
2.7.1 Induction Therapy
2.7.2 Maintenance Therapy
2.7.3 Salvage Therapy
2.8
Present and Future Options for Treating Multiple Myeloma: Summary
3. The World Multiple Myeloma Drug Treatment Market, 2013-2023
3.1
The World Multiple Myeloma Drug Treatment Market in 2012
3.2
Multiple Myeloma Drug Treatment: Overarching Market Forecast 2013-2023
3.3
World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass:
Comparison of Revenue and Market Share, 2018 and 2023
www.visiongain.com

3. Contents
3.4
The World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass:
Grouped Revenue Forecasts, 2013-2023
3.5
Immunomodulators for Multiple Myeloma: Dominating the Market Throughout the
Forecast Period
3.5.1 Immunomodulators: Revenue Forecast 2013-2023
3.6
Proteasome Inhibitors: A Cornerstone in Multiple Myeloma Drug Treatment
3.6.1 Proteasome Inhibitors: Revenue Forecast 2013-2023
3.7
Monoclonal Antibodies: Market Launch Anticipated in 2015
3.7.1 Monoclonal Antibodies: Revenue Forecast 2013-2023
3.8
Kinase Inhibitors: A Class of Advanced Cancer Medications
3.8.1 Kinase Inhibitors: Revenue Forecast 2013-2023
3.9
Summary: Growth of the Multiple Myeloma Drug Treatment Market, 2013-2023
4. Leading National Markets for Multiple Myeloma Drug Treatment,
2013-2023
4.1
The Leading National Markets in 2012
4.2
The Leading National Markets: Comparison of Revenue and Market Share, 2018 and
2023
4.3
The Leading National Markets for Multiple Myeloma Drug Treatment: Grouped
Revenue Forecasts, 2013-2023
4.4
The US Will Continue to Dominate the Multiple Myeloma Drug Treatment Market from
2013-2023
4.5
The EU5 Countries
4.5.1 Germany: The Largest EU5 Market Will Have the Lowest Levels of Growth
4.5.2 France: Steadily Decreasing Market Share
4.5.3 Italy: High Growth Between 2013 and 2016
www.visiongain.com

4. Contents
4.5.4 The UK: Strongest Growth of the EU5 from 2018-2023
4.5.5 Spain: The Smallest Market of the EU5
4.6
Japan: Delays in Regulatory Approval
4.7
China: Pursuing Domestic Oncology R&D
4.8
Brazil: Governmental Healthcare Investments Support Growth
4.9
Russia: Poor Treatment Outcomes Mean Demand for More-Effective Therapy is High
4.10
India: A Strong Domestic Drug Industry Limits Market Share
5. The Leading Drugs of the World Multiple Myeloma Market, 20132023
5.1
Immunomodulators and Proteasome Inhibitors Dominate the Market in 2012
5.2
Leading Multiple Myeloma Drugs: Comparison of Revenue and Market Share, 2018
and 2023
5.3
Leading Multiple Myeloma Drugs: Grouped Revenue Forecasts, 2013-2023
5.4
Revlimid: Market Domination Will Continue
5.4.1 Revlimid: Driving and Restraining Forces
5.4.2 Revlimid: Revenue Forecast 2013-2023
5.5
Velcade: Generic Competition Expected
5.5.1 The Driving and Restraining Factors for Velcade
5.5.2 Velcade: Revenue Forecast 2013-2023
5.6
Thalomid: A 1st Line Treatment, But Revenue is Declining
5.6.1 Driving and Restraining Factors for Thalomid
5.6.2 Thalomid: Revenue Forecast, 2013-2023
5.7
Zometa: Facing Generic Competition
5.7.1 Driving and Restraining Factors for Zometa
www.visiongain.com

5. Contents
5.7.2 Zometa: Revenue Forecast, 2013-2023
Kyprolis: The 2nd Generation Proteasome Inhibitor Will Capture a Large Market Share
5.8
5.8.1 The Driving and Restraining Factors for Kyprolis
5.8.2 Kyprolis: Revenue Forecast, 2013-2023
Pomalyst: Celgene’s 3rd Immunomodulator, But Will it Supersede its Predecessors?
5.9
5.9.1 Driving and Restraining Factors for Pomalyst
5.9.2 Pomalyst: Revenue Forecast 2013-2023
5.10
Promising Drugs in the R&D Pipeline
5.10.1
Elotuzumab: The 1st Monoclonal Antibody For MM?
5.10.1.1
Elotuzumab: Driving and Restraining Forces
5.10.1.2
Elotuzumab: Revenue Forecast, 2013-2023
5.10.2
MLN9708: A Game Changing Proteasome Inhibitor?
5.10.2.1
MLN9708: Driving and Restraining Factors
5.10.2.2
MLN9708: Revenue Forecast, 2013-2023
5.10.3
Panobinostat: A First-in-Class Therapy
5.10.3.1
Panobinostat: Driving and Restraining Factors
5.10.3.2
Panobinostat: Revenue Forecast, 2013-2023
5.10.4
Aplidin: A Marine-Derived Compound for the Treatment of Multiple Myeloma
5.10.4.1
5.10.4.2
5.11
Aplidin: Driving and Restraining Factors
Aplidin: Revenue Forecast, 2013-2023
Late-Stage Product Candidates
6. Multiple Myeloma: R&D Pipeline, 2013
6.1
The Small-Molecule Drug Pipeline
6.1.1 Five Candidates in Phase III Development
www.visiongain.com

6. Contents
6.1.1.1
Novartis’ Panobinostat
6.1.1.2
AB Science’s Masitinib
6.1.1.3
Millennium Pharmaceuticals’ MLN9708 (ixazomib)
6.1.1.4
PharmaMar’s Aplidin
6.1.1.5
Otsuka America Pharmaceutical’s Busulfex
6.1.2 Candidates in Phase II Development: An Abundance of Kinase Inhibitors
6.1.2.1
Oncopeptides’ Melflufen
6.1.2.2
Merck’s Dinaciclib
6.1.2.3
Astra Zeneca’s Selumetinib
6.1.2.4
Pharmacyclics’ Ibrutinib
6.1.2.5
Geron Corporation’s Imetelstat
6.1.2.6
Celgene’s Istodax
6.1.2.7
Bristol-Myers Squibb’s Dasatinib
6.1.2.8
Cephalon’s Treanda
6.1.2.9
Pfizer’s Torisel
6.1.2.10
Novartis’ Everolimus
6.1.2.11
Millennium Pharmaceuticals’ MLN8237
6.1.2.12
Bayer and Onyx Pharmaceuticals’ Nexavar
6.1.3 Candidates in Phase I Development
6.1.3.1
GlaxoSmithKline’s GSK2110183 (afuresertib): Development Apparently
Suspended
6.1.3.2
Array BioPharma’s Arry-520
6.1.3.3
Arno Therapeutics’ AR-42
6.1.3.4
EntreMed’s ENMD-2076
6.1.3.5
Genentech’s Erivedge
www.visiongain.com

7. Contents
6.1.3.6
6.1.3.7
6.2
Allos Therapeutics’ Folotyn
Synta Pharmaceuticals’ Ganetespib
The Biologic Drug Pipeline: Monoclonal Antibodies Dominate
6.2.1 Three Monoclonal Antibodies Dominate the Phase III Developmental Pipeline
6.2.1.1
Elotuzumab Being Developed Under a Collaboration Between Bristol-Myers
Squibb and AbbVie
6.2.1.2
Amgen’s Xgeva: Could it Supersede Zometa?
6.2.1.3
Janssen Biotech and Genmab’s Daratumumab
6.2.2 Candidates in Phase II Development
6.2.2.1
Novartis’ HCD122 (Lucatumumab): Development Appears to Have Stalled
6.2.2.2
Senesco Technologies’ SNS01-T
6.2.2.3
Gliknik’s GL-0817
6.2.2.4
Celldex Therapeutics’ CDX-1401
6.2.2.5
Janssen’s Siltuximab
6.2.2.6
Roche’s Avastin
6.2.2.7
GlaxoSmithKline’s Bexxar
6.2.2.8
Novartis’ BHQ880
6.2.2.9
Cell Genesys’ GVAX
6.2.2.10
Oncovir’s Hiltonol
6.2.3 Candidates in Phase I Development
6.2.3.1
Genentech’s DFRF4539A
6.2.3.2
ImmunoGen’s Lorvotuzumab Mertansine
6.2.3.3
Eli Lilly’s Tabalumab
6.2.3.4
Genentech’s MFGR1877S
6.2.3.5
Oncolytics’ Reolysin
www.visiongain.com

8. Contents
6.3
Future Epigenetics-Based Treatments
7. The Leading Companies of the Multiple Myeloma Drug Treatment
Market, 2013
7.1
The Leading Companies in 2012
7.2
Celgene Corporation is the Market Leader
7.3
Johnson & Johnson: Proteasome and MAb Leader
7.4
Takeda: A Strong Portfolio Through Subsidiary Millennium Pharmaceuticals
7.5
Novartis: A Small Market Share in 2012, But a Well-Stocked Pipeline
7.6
Bristol-Myers Squibb: Poised for Market Entry
7.7
Onyx Pharmaceuticals: Now Part of Amgen
8. Qualitative Analysis of the Multiple Myeloma Drug Treatment
Market
8.1
Strengths and Weaknesses of the Multiple Myeloma Drug Treatment Market, 2013
8.1.1 Proven Commercial Viability of the Multiple Myeloma Drug Treatment Market
8.1.2 Use of Combination Therapies Mean the Market Can Sustain a High Number of
Products
8.1.3 As a Result, The R&D Pipeline is Well Stocked
8.1.4 Governmental Incentives are Helping to Drive this R&D Effort
8.1.5 But Multiple Myeloma Remains an Incurable Disease
8.1.6 Few Products Dominating that Market: a Weakness?
8.2
Opportunities and Threats Facing the Multiple Myeloma Drug Treatment Market,
2013-2023
8.2.1 Oncology is a Growth Area for Investment, Creating Opportunities in the Market
8.2.2 Will Oncology Remain a Strong Investment for Pharma?
www.visiongain.com

9. Contents
8.3
Social, Technological, Economic and Political (STEP) Forces Influencing the Multiple
Myeloma Drug Industry and Market, 2013-2023
8.3.1 Social: Adherence, Support and Education are Crucial
8.3.2 Technological: Increasing Understanding of Cancer Biology
8.3.3 Economic: Stretched Healthcare Budgets Will Affect that Drug Industry
8.3.4 Political: Broadening and Narrowing of Governmental Healthcare Spending
9. Research Interviews from Our Survey
9.1
Interview with Dr Paul Richardson, MD, R.J. Corman Professor of Medicine at Harvard
Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at the
Dana-Farber Cancer Institute
9.1.1 On the Current State of the Multiple Myeloma Drug Market
9.1.2 On the Potential of the Novel Treatments, Pomalidomide and Carfilzomib
9.1.3 On the Future of Multiple Myeloma Treatment
9.2
Interview with an External Authority in the Field (Views Given Anonymously)
9.2.1 Recent Research: Obesity is a Strong Risk Factor for Multiple Myeloma
9.2.2 Multiple Myeloma Treatment: Proactive versus Reactive
9.2.3 Treatment Options for Obese Patients
9.2.4 Multiple Myeloma Incidence Will Increase Owing to Obesity
10. Conclusions from Our Research and Analysis
10.1
The World Multiple Myeloma Drug Treatment Market, 2013-2023
10.2
The Leading National Markets for Multiple Myeloma Drug Treatments, 2013-2023
10.3
The Leading Products in the Multiple Myeloma Drug Treatment Market, 2013-2023
10.4
Trends in the Industry and Market
10.4.1
Multiple Myeloma Treatment is a Thriving Market That Will Continue to Expand
www.visiongain.com

10. Contents
10.4.2
The R&D Pipeline is Large and Diverse
10.4.3
The Small Patient Population Generates Uncertainty
www.visiongain.com

11. Contents
List of Tables
Table 1.1 Currency Exchange Rates,
Table 2.1 Drugs Indicated for the Treatment of Multiple Myeloma: Brand Name, Generic Name
and Therapeutic Class, 2013
Table 3.1 The World Multiple Myeloma Drug Market by Therapeutic Class: Revenue ($m) and
Market Share (%), 2012
Table 3.2 World Multiple Myeloma Drug Market: Overall Revenue Forecast ($m), 2013-2023
Table 3.3 The Multiple Myeloma Drug Market by Therapeutic Class: Comparison of Revenue
($m) and Market Share (%), 2018 and 2023
Table 3.4 Multiple Myeloma Drug Market by Therapeutic Subclass: Group Revenue ($m) and
Market Share (%) Forecasts, 2013-2023
Table 3.5 Immunomodulators for Multiple Myeloma: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 3.6 Proteasome Inhibitors for Multiple Myeloma: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 3.7 Monoclonal Antibodies for Multiple Myeloma: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 3.8 Kinase Inhibitors for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast,
2013-2023
Table 4.1 The Leading National Markets: Revenue ($m) and Market Share (%), 2012
Table 4.2 The Leading National Markets: Comparison of Revenue ($m) and Market Share (%),
2018 and 2023
Table 4.3 The Leading National Markets: Grouped Revenue Forecasts ($m), 2013-2023
Table 4.4 The US Multiple Myeloma Drug Treatment Market: Revenue ($m) and Market Share
(%) Forecast, 2013-2023
Table 4.5 The EU5 Multiple Myeloma Market by Country: Revenue ($m) and Market Share (%)
Forecasts, 2013-2023
Table 4.6 The German Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
www.visiongain.com

12. Contents
Table 4.7 The French Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.8 The Italian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.9 The UK Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.10 The Spanish Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.11 The Japanese Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.12 The Chinese Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.13 The Brazilian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.14 The Russian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 4.15 The Indian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2023
Table 5.1 The Leading Drugs for Multiple Myeloma: Revenue ($m) and Market Share (%), 2012
Table 5.2 Leading Drugs for MM: Comparison of Revenue ($m) and Market Share (%), 2018 and
2023
Table 5.3 Leading MM Drugs: Grouped Revenue Forecasts ($m), 2013-2023
Table 5.4 Revlimid: Key Facts
Table 5.5 Revlimid: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.6 Velcade: Key Facts
Table 5.7 Velcade: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.8 Thalomid: Key Facts
Table 5.9 Thalomid: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.10 Zometa: Key Facts
Table 5.11 Zometa: Revenue ($m) and Market Share (%) Forecast, 2013-2023
www.visiongain.com

13. Contents
Table 5.12 Kyprolis: Key Facts
Table 5.13 Kyprolis: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.14 Pomalyst: Key Facts
Table 5.15 Pomalyst: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.16 Elotuzumab: Key Facts
Table 5.17 Elotuzumab: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.18 MLN9708: Key Facts
Table 5.19 MLN9708: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.20 Panobinostat: Key Facts
Table 5.21 Panobinostat: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.22 Aplidin: Key Facts
Table 5.23 Aplidin: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 6.1 Small Molecule Candidates in Phase III Development For MM, 2013
Table 6.2 Small Molecule Candidates in Phase II Development for MM, 2013
Table 6.3 Small Molecule Candidates in Phase I Development for MM, 2013
Table 6.4 Biologic Candidates in Phase III Development for MM, 2013
Table 6.5 Biologic Candidates in Phase II Development for MM, 2013
Table 6.6 Biologic Candidates in Phase I Development for MM, 2013
Table 7.1 The Leading Companies in the MM Drug Market: Revenue ($m) and Market Share
(%), 2012
Table 7.2 Celgene: Multiple Myeloma Product Portfolio, 2013
Table 7.3 Johnson & Johnson: Multiple Myeloma Product Portfolio, 2013
Table 7.4 Takeda: Multiple Myeloma Product Portfolio, 2013
Table 7.5 Novartis: Multiple Myeloma Product Portfolio, 2013
Table 7.6 Bristol-Myers Squibb: Multiple Myeloma Product Portfolio, 2013
Table 7.7 Amgen: Multiple Myeloma Product Portfolio, 2013
Table 8.1 Strengths and Weaknesses of the Multiple Myeloma Drug Treatment Market, 2013
Table 8.2 Opportunities and Threats Facing the Multiple Myeloma Drug Treatment Market,
2013-2023
www.visiongain.com

14. Contents
Table 8.3 The Social, Technological, Economic and Political Factors Influencing the MM Drug
Treatment Market, 2013-2023
www.visiongain.com

15. Contents
List of Figures
Figure 2.1 The Incidence Rate of Multiple Myeloma (per 100,000) by World Region, 2008
Figure 3.1 The World Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%),
2012
Figure 3.2 The World Multiple Myeloma Drug Treatment Market: Revenue Forecast ($m), 20132023
Figure 3.3 The Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2018
Figure 3.4 The Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2023
Figure 3.5 The Multiple Myeloma Drug Market by Therapeutic Class: Revenue Forecasts ($m),
2013-2023
Figure 3.6 Immunomodulators for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.7 Proteasome Inhibitors for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.8 Monoclonal Antibodies for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.9 Kinase Inhibitors for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.10 The Multiple Myeloma Drug Treatment Market: Driving and Restraining Factors,
2013
Figure 4.1 The Leading National Markets: Market Shares (%), 2012
Figure 4.2 The Leading National Markets for Multiple Myeloma: Market Share (%), 2018
Figure 4.3 The Leading National Markets for Multiple Myeloma: Market Share (%), 2023
Figure 4.4 The US Multiple Myeloma Drug Treatment Market: Revenue Forecast ($m), 20132023
Figure 4.5 US: Multiple Myeloma Drug Market Penetration – Usage of Revlimid, Velcade and
Thalomid in Early Stage of Disease (%), 2011
Figure 4.6 US: Multiple Myeloma Drug Market Penetration – Usage of Revlimid, Velcade and
Thalomid in Late Stages of Disease (%), 2011
Figure 4.7 The EU5 Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.8 The German Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.9 The French Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.10 The Italian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
www.visiongain.com

16. Contents
Figure 4.11 The UK Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.12 The Spanish Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.13 The Japanese Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.14 The Chinese Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.15 The Brazilian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.16 The Russian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.17 The Indian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 5.1 The Leading Drugs for MM: Market Share (%), 2012
Figure 5.2 Leading Drugs for MM: Market Share (%), 2018
Figure 5.3 Leading MM Drugs: Market Share (%), 2023
Figure 5.4 Revlimid: Drivers and Restraints, 2013-2023
Figure 5.5 Revlimid: Revenue Forecast ($m), 2013-2023
Figure 5.6 Velcade: Driving and Restraining Forces, 2013-2023
Figure 5.7 Velcade: Revenue Forecast ($m), 2013-2023
Figure 5.8 Thalomid: Driving and Restraining Forces, 2013-2023
Figure 5.9 Thalomid: Revenue Forecast ($m), 2013-2023
Figure 5.10 Zometa: Driving and Restraining Forces, 2013-2023
Figure 5.11 Zometa: Revenue Forecast ($m), 2013-2023
Figure 5.12 Kyprolis: Driving and Restraining Factors, 2013-2023
Figure 5.13 Kyprolis: Revenue Forecast ($m), 2013-2023
Figure 5.14 Pomalyst: Driving and Restraining Forces, 2013-2023
Figure 5.15 Pomalyst: Revenue Forecast ($m), 2013-2023
Figure 5.16 Elotuzumab: Driving and Restraining Forces, 2013-2023
Figure 5.17 Elotuzumab: Revenue Forecast ($m), 2013-2023
Figure 5.18 MLN9708: Driving and Restraining Factors, 2013-2023
Figure 5.19 MLN9708: Revenue Forecast ($m), 2013-2023
Figure 5.20 Panobinostat: Driving and Restraining Forces, 2013-2023
Figure 5.21 Panobinostat: Revenue Forecast ($m), 2013-2023
Figure 5.22 Aplidin: Driving and Restraining Forces, 2013-2023
Figure 5.23 Aplidin: Revenue Forecast ($m), 2013-2023
www.visiongain.com

17. Contents
Figure 6.1 Breakdown of Small Molecule Drug Pipeline by Development Phase (%), 2013
Figure 6.2 Breakdown of Biologic Drug Pipeline by Development Phase (%), 2013
Figure 7.1 Leading Companies in the MM Drug Market: Market Share (%), 2012
Figure 10.1 The World MM Drug Treatment Market: Breakdown of Revenue ($m) by Therapeutic
Class, 2012
Figure 10.2 The MM Drug Treatment Market: Revenue ($m) by Country, 2012, 2018 and 2023
Figure 10.3 Leading Drugs of the Multiple Myeloma Market: Comparison of Revenue ($m),
2012, 2018 and 2023
www.visiongain.com

18. Contents
Companies and Organisations Mentioned in the Report
AB Science
Abbott Laboratories
AbbVie
Abramsom Cancer Centre
Abraxis
Actavis
Allos Therapeutics
Amgen
Anthrogenesis
Arno Therapeutics
Array Biopharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
Biotest Pharmaceuticals
Bristol-Myers Squibb
Broad Institute
Cancer Research UK
Celanese
Celgene
Cell Genesys
Celldex Therapeutics
Cephalon
Constellation Pharmaceuticals
Cougar Biotechnology
Dana-Farber Cancer Institute
www.visiongain.com

19. Contents
Dr. Reddy’s Laboratories
Eli Lilly
Emcure Pharmaceuticals
Entremed
EntreMed
Epizyme
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Galapagos
Genentech
Genmab
Geron Corporation
GlaxoSmithKline (GSK)
Gliknik
Gloucester Pharmaceuticals
Harvard Medical School
Hospira
Human Genome Sciences
Immune System Therapeutics
ImmunoGen
Immunomedics
Janssen Biotech
Jerome Lipper Centre for Multiple Myeloma
Johnson & Johnson
Karyopharm Therapeutics
Kyowa Hakko Kirin Pharma
Kyowa Hakko Kirin Pharma
Leukosite
Lipomed
MD Anderson Cancer Centre
www.visiongain.com

20. Contents
Merck & Co.
Millennium Pharmaceuticals
MorphoSys
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Mylan
Myogenics/ ProScript
Natco Pharma
National Institute for Health and Care Excellence (NICE)
Nereus Pharmaceuticals
Novartis
Oncolytics
OncoPep
Oncopeptides
Oncovir
Onyx Pharmaceuticals
Otsuka America Pharmaceutical
PDL BioPharma
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacyclics
PharmaMar
Pharmion
Pharmion
Roche
Rockefeller University
Seattle Genetics
Senesco Technologies
Signal Pharmaceuticals
Sun Pharma Global
www.visiongain.com

21. Contents
Synta Pharmaceuticals
Takeda
Teva Pharmaceuticals
The World Health Organization (WHO)
Threshold Pharmaceuticals
Translational Genomics Research Institute
University of Arkansas
University of Illinois
US National Comprehensive Cancer Network
Watson Pharmaceuticals
www.visiongain.com

22. Multiple Myeloma Treatments: World Drug
Industry and Market 2013-2023
thalidomide, and supplies patients with educational materials relating to the product and required to
sign an informed consent form. Women are required to use at least two methods of contraception
and undergo periodic pregnancy tests when using the product, owing to reported teratogenicity.
Following these measures would erode the profit margins for any company manufacturing generic
thalidomide.
Figure 5.8 Thalomid: Driving and Restraining Forces, 2013-2023
Drivers
• Generic challenge is disincentivised by the
necessity of running a drug monitoring program.
• The drug is used as a 1st line treatment, whereas
Revlimid and Pomalyst are approved as 2nd and
3rd line treatments, respectively.
• It is less expensive than the follow-on Celgene
products and may thus be used in the emerging
markets.
Restraints
• Revlimid is an improved version of Thalomid,
limiting the commercial scope for the older
product.
• The recent approval of the next immunomodulator,
Pomalyst, will further reduce demand for
Thalomid.
• Generic versions of the product are an option for a
company who sees it as commercially viable.
Source: visiongain 2013
5.6.2 Thalomid: Revenue Forecast, 2013-2023
Thalomid will see negative annual growth throughout the forecast period, with revenue steadily
contracting over the next 10 years. This will result from competition from the next generation
immunomodulators Revlimid and Velcade, and increasing off-label use of competitor compounds in
st
1 line treatment for MM. Between 2013 and 2018, revenue will contract at a CAGR of -13.2%. It is
likely that Thalomid will see generic competition during the forecast period, with European patents
for the drug set to expire in 2019. This generic competition will drive revenue contraction in the
second half of the forecast period. The rate of contraction will slow in the latter half of the forecast
period with revenue contracting at a CAGR of -10.8% between 2018 and 2023. In 2023, sales of
Thalomid for the treatment of MM will generate revenue of $70m, accounting for 0.49% of the total
market.
www.visiongain.com
Page 85

23. Multiple Myeloma Treatments: World Drug
Industry and Market 2013-2023
Table 5.9 Thalomid: Revenue ($m) and Market Share (%) Forecast, 2013-2023
2012
Market Share (%) 4.69
Revenue ($m)
287
AGR (%)
CAGR (%)
2013
3.68
253
-12
2014
2.81
220
-13
2015
2.06
191
-13
2016
1.49
164
-14
2017 2018
1.22 1.03
141
124
-14
-12
-13.20
2019 2020 2021 2022 2023
0.85 0.74 0.64 0.56 0.49
109 99
88
79
70
-12 -10 -11 -10
-11
-10.80
Source: visiongain 2013; estimate of revenue from indications of MM only
Figure 5.9 Thalomid: Revenue Forecast ($m), 2013-2023
350
300
Revenue ($m)
250
200
150
100
50
0
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Year
Source: visiongain 2013; estimate of revenue from indications of MM only
5.7 Zometa: Facing Generic Competition
Zometa (zoledronic acid) is a bisphosphonate which reduces the turnover of bone. It is used in
oncology to reduce or delay skeletal-related events (bone pain or fractures as a result of
weakening) in patients with bone metastases from solid tumours, such as breast or prostate
cancer, and multiple myeloma. In addition, it is used to treat hypercalcaemia of malignancy (HCM),
a condition in which blood calcium levels are raised due to cancer. Therefore, Zometa is used in
the treatment regimen for many cancers. Launched on the EU market in 2001 and the US in 2003,
Zometa is marketed by Novartis. The company has reported previously that indications of MM
account for approximately 21% of the drugs total revenue. This is the figure that visiongain has
used to determine revenue in 2012, our base year. In 2012, revenue generated by Zometa
declined as a result of competition.
www.visiongain.com
Page 86